About Fibrocell (NASDAQ:FCSC)
Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FCSC
CUSIPN/A
Phone484-713-6000
Debt
Debt-to-Equity RatioN/A
Current Ratio4.05%
Quick Ratio4.05%
Price-To-Earnings
Trailing P/E Ratio-0.34
Forward P/E Ratio-0.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$350,000.00
Price / Sales45.38
Cash FlowN/A
Price / CashN/A
Book Value$0.35 per share
Price / Book1.60
Profitability
EPS (Most Recent Fiscal Year)($1.65)
Net Income$-16,240,000.00
Net MarginsN/A
Return on Equity-649.57%
Return on Assets-111.79%
Miscellaneous
Employees20
Outstanding Shares28,360,000
Fibrocell (NASDAQ:FCSC) Frequently Asked Questions
What is Fibrocell's stock symbol?
Fibrocell trades on the NASDAQ under the ticker symbol "FCSC."
How were Fibrocell's earnings last quarter?
Fibrocell (NASDAQ:FCSC) released its quarterly earnings data on Monday, March, 19th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.42. View Fibrocell's Earnings History.
When is Fibrocell's next earnings date?
What price target have analysts set for FCSC?
3 analysts have issued 12 month target prices for Fibrocell's stock. Their predictions range from $6.00 to $7.00. On average, they anticipate Fibrocell's share price to reach $6.50 in the next twelve months. View Analyst Ratings for Fibrocell.
Who are some of Fibrocell's key competitors?
Some companies that are related to Fibrocell include Regulus Therapeutics (RGLS), Vascular Biogenics (VBLT), Genprex (GNPX), Sophiris Bio (SPHS), vTv Therapeutics (VTVT), Acerus Pharmaceuti (TRLPF), Scynexis (SCYX), Arcturus Therapeutics (ARCT), LifeVantage (LFVN), Versartis (VSAR), Pain Therapeutics (PTIE), KaloBios (HGEN), Addex Pharmaceuticals (ADDXF), Immutep (IMMP) and Zosano Pharma (ZSAN).
Who are Fibrocell's key executives?
Fibrocell's management team includes the folowing people:
- Mr. John Michael Maslowski, Pres, CEO, PFO, Principal Accounting Officer & Director (Age 43)
- Mr. Robert G. Partridge, VP of Global Marketing, Communications and Investor Relations
- Ms. Elizabeth A. Browning, Exec. VP of Marketing
- Ms. Michele Mchugh-Mazzatta, VP of Sales
- Dr. Pierre Compte, Managing Director of Switzerland
Has Fibrocell been receiving favorable news coverage?
Media coverage about FCSC stock has been trending somewhat negative recently, Accern reports. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fibrocell earned a media sentiment score of -0.10 on Accern's scale. They also assigned media stories about the company an impact score of 47.60 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Fibrocell?
Shares of FCSC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fibrocell's stock price today?
One share of FCSC stock can currently be purchased for approximately $0.56.
How big of a company is Fibrocell?
Fibrocell has a market capitalization of $16.73 million and generates $350,000.00 in revenue each year. The company earns $-16,240,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Fibrocell employs 20 workers across the globe.
How can I contact Fibrocell?
Fibrocell's mailing address is 405 EAGLEVIEW BOULEVARD, EXTON PA, 19341. The company can be reached via phone at 484-713-6000 or via email at [email protected]
MarketBeat Community Rating for Fibrocell (FCSC)
MarketBeat's community ratings are surveys of what our community members think about Fibrocell and other stocks. Vote "Outperform" if you believe FCSC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FCSC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Fibrocell (NASDAQ:FCSC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Fibrocell in the last 12 months. Their average twelve-month price target is $6.50, suggesting that the stock has a possible upside of 1,060.71%. The high price target for FCSC is $7.00 and the low price target for FCSC is $6.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.50 | $6.50 | $5.00 | $5.5333 |
| Price Target Upside: | 1,060.71% upside | 983.33% upside | 566.67% upside | 83.22% upside |
Fibrocell (NASDAQ:FCSC) Consensus Price Target History
Fibrocell (NASDAQ:FCSC) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Fibrocell (NASDAQ:FCSC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Fibrocell (NASDAQ FCSC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 44.44%
Fibrocell (NASDAQ FCSC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/11/2017 | Randal J Kirk | Major Shareholder | Buy | 2,727,273 | $0.77 | $2,100,000.21 | |  |
| 12/2/2016 | David Pernock | Chairman | Buy | 50,000 | $0.92 | $46,000.00 | 105,600 | |
| 11/13/2015 | David Pernock | CEO | Buy | 3,000 | $5.00 | $15,000.00 | 55,600 | |
| 8/11/2015 | David Pernock | CEO | Buy | 3,500 | $6.54 | $22,890.00 | | |
| 7/27/2015 | Randal J Kirk | Major Shareholder | Buy | 975,987 | $5.80 | $5,660,724.60 | | |
| 5/13/2015 | David Pernock | CEO | Buy | 16,600 | $4.30 | $71,380.00 | | |
| 12/12/2014 | David Pernock | CEO | Buy | 5,000 | $2.52 | $12,600.00 | | |
| 11/20/2014 | David Pernock | CEO | Buy | 5,000 | $2.54 | $12,700.00 | | |
| 11/20/2014 | John Michael Maslowski | VP | Buy | 1,000 | $2.54 | $2,540.00 | | |
| 6/5/2014 | Christine St.Clare | Director | Buy | 10,000 | $3.00 | $30,000.00 | | |
| 6/5/2014 | David Pernock | CEO | Buy | 12,500 | $2.95 | $36,875.00 | | |
| 6/4/2014 | Kelvin Moore | Director | Buy | 4,557 | $2.99 | $13,625.43 | | |
| 6/4/2014 | Randal J Kirk | Major Shareholder | Buy | 400,000 | $2.90 | $1,160,000.00 | | |
| 1/24/2014 | Randal J Kirk | Major Shareholder | Buy | 1,024,590 | $4.88 | $4,999,999.20 | | |
| 11/21/2013 | David Pernock | CEO | Buy | 10,000 | $3.69 | $36,900.00 | | |
| 11/20/2013 | Gregory L Weaver | CFO | Buy | 10,000 | $3.51 | $35,100.00 | | |
| 10/1/2013 | Randal J Kirk | Major Shareholder | Buy | 3,658,536 | $4.10 | $14,999,997.60 | | |
| 7/26/2013 | Randal J Kirk | Major Shareholder | Buy | 1,243,781 | $6.03 | $7,499,999.43 | | |
(Data available from 1/1/2013 forward)
Fibrocell (NASDAQ FCSC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Fibrocell (FCSC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 19 at 12:28 AM |
 | Form 8-K Fibrocell Science, Inc. For: Apr 18
www.streetinsider.com - April 18 at 5:45 PM |
 | Health Care Sector Update for 04/18/2018: SLDB,FCSC,ABT,ENDP,EGRX
www.nasdaq.com - April 18 at 5:45 PM |
 | BRIEF-Fibrocell Announces Review Of Strategic Alternatives
www.reuters.com - April 18 at 5:45 PM |
 | Fibrocell Announces Review of Strategic Alternatives
globenewswire.com - April 18 at 8:16 AM |
 | Fibrocell Science shares halted pending news
seekingalpha.com - April 18 at 8:10 AM |
| Fibrocell (FCSC) Expected to Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - April 16 at 9:21 AM |
| Fibrocell Science (FCSC) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - April 14 at 8:37 PM |
| Fibrocell Science (FCSC) Given a $6.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 11 at 7:53 PM |
| Fibrocell Science (FCSC) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 10 at 5:02 PM |
 | Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA
finance.yahoo.com - April 10 at 8:27 AM |
| Fibrocell Science (FCSC) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - April 9 at 11:35 AM |
| Fibrocell Science (FCSC) Receives "Buy" Rating from Griffin Securities
www.americanbankingnews.com - April 6 at 9:10 AM |
| Zacks: Analysts Anticipate Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - March 30 at 1:20 PM |
| Reviewing OptiNose (OPTN) & Fibrocell Science (FCSC)
www.americanbankingnews.com - March 30 at 9:38 AM |
| Fibrocell Science (FCSC) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - March 28 at 2:06 PM |
| Zacks Investment Research Lowers Fibrocell Science (FCSC) to Hold
www.americanbankingnews.com - March 24 at 12:28 AM |
| Fibrocell Science's (FCSC) CEO John Maslowski on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 20 at 8:28 AM |
| Fibrocell Science (FCSC) Releases Earnings Results, Beats Estimates By $0.38 EPS
www.americanbankingnews.com - March 19 at 1:48 PM |
| HC Wainwright Analysts Give Fibrocell Science (FCSC) a $6.00 Price Target
www.americanbankingnews.com - March 19 at 1:03 PM |
 | Earnings Scheduled For March 19, 2018 - Benzinga
www.benzinga.com - March 19 at 8:22 AM |
| Does Fibrocell Science Inc’s (NASDAQ:FCSC) Past Performance Indicate A Stronger Future?
finance.yahoo.com - March 19 at 8:22 AM |
| Fibrocell Reports 2017 Financial Results and Recent Highlights
finance.yahoo.com - March 19 at 8:22 AM |
| Pre-Market Earnings Report for March 19, 2018 : CSIQ, MDWD, LEJU, FCSC - Nasdaq
www.nasdaq.com - March 17 at 8:26 AM |
| Fibrocell Science Inc (FCSC) Sees Large Decrease in Short Interest
www.americanbankingnews.com - March 14 at 1:38 AM |
| Fibrocell Science (FCSC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 13 at 10:52 PM |
| Zacks: Brokerages Expect Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - March 13 at 12:03 PM |
| Fibrocell Science (FCSC) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 13 at 10:56 AM |
| Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and ... - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:25 AM |
| Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and ... - Nasdaq
www.nasdaq.com - March 12 at 9:02 AM |
| Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent Highlights
finance.yahoo.com - March 12 at 9:02 AM |
| Fibrocell Science (FCSC) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 7 at 11:22 PM |
| Fibrocell Science (FCSC) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 6 at 10:52 PM |
| Fibrocell Science's (FCSC) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - March 6 at 3:28 PM |
| Fibrocell Science (FCSC) Announces FDA Allowance of IND for FCX-013 for Treatment of Moderate to Severe ... - StreetInsider.com
www.streetinsider.com - March 6 at 8:15 AM |
| Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
finance.yahoo.com - March 6 at 8:15 AM |
| Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat - Nasdaq
www.nasdaq.com - March 3 at 8:16 AM |
| Fibrocell Science (FCSC) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:40 AM |
 | What's in Store for Intrexon (XON) This Earnings Season?
www.msn.com - February 27 at 8:19 AM |
| Comparing Organovo (ONVO) & Fibrocell Science (FCSC)
www.americanbankingnews.com - February 17 at 12:26 PM |
| Fibrocell Science (FCSC) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 14 at 11:42 PM |
| Zacks Investment Research Upgrades Fibrocell Science (FCSC) to Buy
www.americanbankingnews.com - February 14 at 12:28 AM |
| Zacks: Brokerages Anticipate Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - February 7 at 11:16 AM |
| Fibrocell Science (FCSC) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 6 at 11:06 PM |
| Fibrocell to Present at 20th Annual BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:28 AM |
| Fibrocell Science (FCSC) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - February 5 at 11:24 PM |
| BRIEF-Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin Disorder
www.reuters.com - February 5 at 9:34 AM |
| Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
finance.yahoo.com - February 5 at 9:34 AM |
| Wired News – Fibrocell Science Gets FDA Allowance to Start Pediatric Enrollment in Phase-1/2 Clinical Trial of FCX-007 for the Treatment of RDEB
finance.yahoo.com - February 1 at 9:40 AM |
| Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
finance.yahoo.com - January 30 at 9:22 AM |
Fibrocell (NASDAQ:FCSC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Fibrocell (NASDAQ:FCSC) Income Statement, Balance Sheet and Cash Flow Statement
Fibrocell (NASDAQ FCSC) Stock Chart for Thursday, April, 26, 2018
Loading chart…
